52 related articles for article (PubMed ID: 24813466)
1. ¹⁸F-fluoromethylcholine or ¹⁸F-fluoroethylcholine pet for prostate cancer imaging: which is better? A literature revision.
Evangelista L; Cervino AR; Guttilla A; Zattoni F; Cuccurullo V; Mansi L
Nucl Med Biol; 2015 Apr; 42(4):340-8. PubMed ID: 25618796
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and therapeutic impact of PET/CT with 18F-DCFPyL versus 18F-Fluorocholine in initial staging of intermediate-/high-risk prostate cancer: a pilot study.
Lucas Lucas C; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM; García Vicente AM
Ann Nucl Med; 2023 Oct; 37(10):551-560. PubMed ID: 37532975
[TBL] [Abstract][Full Text] [Related]
3. Unusual uptakes on
Roland A; Drouet C; Boulahdour H; Cochet A; De Bari B
Quant Imaging Med Surg; 2021 Jan; 11(1):172-182. PubMed ID: 33392020
[TBL] [Abstract][Full Text] [Related]
4. Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study.
Triggiani L; Mazzola R; Magrini SM; Ingrosso G; Borghetti P; Trippa F; Lancia A; Detti B; Francolini G; Matrone F; Bortolus R; Fanetti G; Maranzano E; Pasqualetti F; Paiar F; Bonù ML; Magli A; Bruni A; Mazzeo E; Franzese C; Scorsetti M; Alongi F; Jereczek-Fossa BA; Ost P; Buglione M
World J Urol; 2019 Dec; 37(12):2631-2637. PubMed ID: 30859273
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography in prostate cancer: An update on state of the art.
Das CJ; Razik A; Sharma S
Indian J Urol; 2018; 34(3):172-179. PubMed ID: 30034126
[TBL] [Abstract][Full Text] [Related]
6. Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.
De Bari B; Mazzola R; Aiello D; Fersino S; Gregucci F; Alongi P; Nicodemo M; Cavalleri S; Salgarello M; Alongi F
Radiol Med; 2018 Sep; 123(9):719-725. PubMed ID: 29687208
[TBL] [Abstract][Full Text] [Related]
7. Molecular imaging of prostate cancer.
Boustani AM; Pucar D; Saperstein L
Br J Radiol; 2018 Apr; 91(1084):20170736. PubMed ID: 29243485
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study.
Triggiani L; Alongi F; Buglione M; Detti B; Santoni R; Bruni A; Maranzano E; Lohr F; D'Angelillo R; Magli A; Bonetta A; Mazzola R; Pasinetti N; Francolini G; Ingrosso G; Trippa F; Fersino S; Borghetti P; Ghirardelli P; Magrini SM
Br J Cancer; 2017 Jun; 116(12):1520-1525. PubMed ID: 28449007
[TBL] [Abstract][Full Text] [Related]
9. Targeting Phospholipid Metabolism in Cancer.
Cheng M; Bhujwalla ZM; Glunde K
Front Oncol; 2016; 6():266. PubMed ID: 28083512
[TBL] [Abstract][Full Text] [Related]
10. Target Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular Imaging.
Amzalag G; Rager O; Tabouret-Viaud C; Wissmeyer M; Sfakianaki E; de Perrot T; Ratib O; Miralbell R; Giovacchini G; Garibotto V; Zilli T
Front Oncol; 2016; 6():73. PubMed ID: 27065024
[TBL] [Abstract][Full Text] [Related]
11. Intensity-modulated salvage radiotherapy with simultaneous integrated boost for local recurrence of prostate carcinoma: a pilot study on the place of PET-choline for guiding target volume delineation.
Wahart A; Guy JB; Vallard A; Geissler B; Ben Mrad M; Falk AT; Prevot N; de Laroche G; Rancoule C; Chargari C; Magné N
Br J Radiol; 2016; 89(1058):20150579. PubMed ID: 26648528
[TBL] [Abstract][Full Text] [Related]
12. The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy.
Mazzola R; Fersino S; Fiorentino A; Ricchetti F; Giaj Levra N; Di Paola G; Sicignano G; Naccarato S; Ruggieri R; Alongi F
Clin Transl Oncol; 2016 Mar; 18(3):317-21. PubMed ID: 26250766
[TBL] [Abstract][Full Text] [Related]
13. Choline metabolism-based molecular diagnosis of cancer: an update.
Glunde K; Penet MF; Jiang L; Jacobs MA; Bhujwalla ZM
Expert Rev Mol Diagn; 2015 Jun; 15(6):735-47. PubMed ID: 25921026
[TBL] [Abstract][Full Text] [Related]
14. Choline-PET in prostate cancer management: the point of view of the radiation oncologist.
De Bari B; Alongi F; Lestrade L; Giammarile F
Crit Rev Oncol Hematol; 2014 Sep; 91(3):234-47. PubMed ID: 24813466
[TBL] [Abstract][Full Text] [Related]
15. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
16. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen kinetics and choline PET/CT in patients with biochemical relapse after primary treatment for prostate cancer.
Castellucci P; Fuccio C; Marzola MC; Al-Nahhas A; Rubello D; Fanti S
Nucl Med Commun; 2011 Jun; 32(6):475-8. PubMed ID: 21394046
[TBL] [Abstract][Full Text] [Related]
19. PET-CT for treatment planning in prostate cancer.
Picchio M; Crivellaro C; Giovacchini G; Gianolli L; Messa C
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):245-68. PubMed ID: 19293771
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
